ZGC TEC LEASING (01601) and Xinjiang Junrui Zhongyan Mining Equipment have entered into a finance leasing agreement.
Zhongguancun Technology Leasing (01601) has announced that on December 30, 2025, the company, as lessor, entered into a financing lease agreement II with the lessee (Xinjiang Junrui Zhongyan Mining Equipment Co., Ltd.). According to the agreement, the lessor will purchase the lessee's own leasing assets II for a transfer price of RMB 40 million; and the lessor will lease back leasing assets II to the lessee for a lease term of 18 months, with a total leasing payment of approximately RMB 41.76 million. Leasing assets II include excavators, mining trucks, and other equipment.
ZGC TEC LEASING (01601) announced that on December 30, 2025, the company entered into a financing lease agreement II as the lessor with the lessee (Xinjiang Junrui Zhongyan Mining Equipment Co., Ltd.). According to this agreement, the lessor will purchase the lessee's own leasing asset II at a transfer price of 40 million RMB; and the lessor will lease the asset II back to the lessee for a lease term of 18 months, with a total lease payment of approximately 41.76 million RMB. The leasing asset II includes excavators, mining trucks and other equipment.
Related Articles
MicroPort CardioFlow-TAVR (02160): The VitaFlow series of transcatheter aortic valve and delivery systems has entered 35 countries and regions worldwide, with a cumulative implantation of nearly 1300 cases.
CHINA NEXT-GEN (03928) announced its annual performance, with a net loss of approximately 880,900 Singapore dollars, an increase of 12.34% compared to the previous year.
Minimally Invasive Heart Communication-B (02160): The one-year follow-up results of the AltaValveTM early feasibility study have been officially announced.
MicroPort CardioFlow-TAVR (02160): The VitaFlow series of transcatheter aortic valve and delivery systems has entered 35 countries and regions worldwide, with a cumulative implantation of nearly 1300 cases.
CHINA NEXT-GEN (03928) announced its annual performance, with a net loss of approximately 880,900 Singapore dollars, an increase of 12.34% compared to the previous year.
Minimally Invasive Heart Communication-B (02160): The one-year follow-up results of the AltaValveTM early feasibility study have been officially announced.
